mTOR Inhibitors Synergize on Regression, Reversal of Gene Expression, and Autophagy in Hepatocellular Carcinoma
暂无分享,去创建一个
S. Thorgeirsson | P. Mischel | B. Aronow | K. Tanaka | G. Thomas | S. Kozma | A. Iwanami | T. Matsutani | J. Andersen | Jang-June Park | E. Conner | C. Mercer | H. Thomas | L. Carnevalli | S. Maira | L. Manway
[1] M. Broggini,et al. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. , 2011, Cancer research.
[2] F. Khuri,et al. The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo , 2011, PloS one.
[3] Daniel J. Klionsky,et al. Relieving Autophagy and 4EBP1 from Rapamycin Resistance , 2011, Molecular and Cellular Biology.
[4] J. Llovet,et al. Targeted therapies for hepatocellular carcinoma. , 2011, Gastroenterology.
[5] Keiji Tanaka,et al. Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells , 2011, The Journal of cell biology.
[6] Y. Eishi,et al. Autophagy-deficient mice develop multiple liver tumors. , 2011, Genes & development.
[7] B. Viollet,et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.
[8] Insil Kim,et al. Mitochondrial degradation by autophagy (mitophagy) in GFP-LC3 transgenic hepatocytes during nutrient deprivation. , 2011, American journal of physiology. Cell physiology.
[9] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[10] C. James,et al. Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma , 2010, Science Signaling.
[11] S. Thorgeirsson,et al. An Integrated Genomic and Epigenomic Approach Predicts Therapeutic Response to Zebularine in Human Liver Cancer , 2010, Science Translational Medicine.
[12] L. Schwartz,et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Blonski,et al. Non-viral causes of hepatocellular carcinoma. , 2010, World journal of gastroenterology.
[14] N. Sonenberg,et al. mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs , 2010, Science.
[15] N. Sonenberg,et al. S6K1 plays a critical role in early adipocyte differentiation. , 2010, Developmental cell.
[16] B. Viollet,et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. , 2010, Cell metabolism.
[17] Chang Hwa Jung,et al. mTOR regulation of autophagy , 2010, FEBS letters.
[18] M. Karin,et al. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. , 2010, Cancer cell.
[19] Jun Hee Lee,et al. Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.
[20] T. Chou. Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.
[21] T. Noda,et al. A subdomain of the endoplasmic reticulum forms a cradle for autophagosome formation , 2009, Nature Cell Biology.
[22] William C Hahn,et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. , 2009, Cancer research.
[23] P. Dennis,et al. A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy , 2009, Autophagy.
[24] C. Chresta,et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) , 2009, The Biochemical journal.
[25] Svati H Shah,et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. , 2009, Cell metabolism.
[26] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[27] D. Guertin,et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. , 2009, Cancer cell.
[28] Robbie Loewith,et al. Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2 , 2009, PLoS biology.
[29] S. Thorgeirsson,et al. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. , 2008, Gastroenterology.
[30] Gareth Griffiths,et al. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum , 2008, The Journal of cell biology.
[31] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[32] J. Zavadil,et al. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy , 2008, The Journal of cell biology.
[33] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[34] Robin Mathew,et al. Role of autophagy in cancer , 2007, Nature Reviews Cancer.
[35] H. El‐Serag. Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[36] A. Hackshaw,et al. A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC) , 2007 .
[37] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[38] S. Carr,et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. , 2007, Molecular cell.
[39] Timothy J. Griffin,et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 , 2007, Nature Cell Biology.
[40] G. Thomas,et al. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. , 2006, Cell metabolism.
[41] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[42] F. Natt,et al. Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[43] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] H. Lane,et al. The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.
[45] H. Hung. Treatment modalities for hepatocellular carcinoma. , 2005, Current cancer drug targets.
[46] S. Thorgeirsson,et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.
[47] S. Thorgeirsson,et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.
[48] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[49] R. Abraham,et al. The Rapamycin-Binding Domain Governs Substrate Selectivity by the Mammalian Target of Rapamycin , 2002, Molecular and Cellular Biology.
[50] G. Thomas,et al. Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. , 2002, Genes & development.
[51] H. El‐Serag. Epidemiology of hepatocellular carcinoma. , 2001, Clinics in liver disease.
[52] A. Meijer,et al. Phosphorylation of Ribosomal Protein S6 Is Inhibitory for Autophagy in Isolated Rat Hepatocytes (*) , 1995, The Journal of Biological Chemistry.
[53] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[54] Tara L. Kieffer,et al. Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis , 2009 .
[55] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[56] H. Lane,et al. The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation , 2005 .
[57] K. Rao,et al. Carcinogenicity of diethylnitrosamine in newborn, infant, and adult mice , 2004, Journal of Cancer Research and Clinical Oncology.
[58] N. Fausto,et al. Mouse Liver Tumorigenesis: Models, Mechanisms, and Relevance to Human Disease , 1999, Seminars in liver disease.
[59] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .